-
Kinase activities in pancreatic ductal adenocarcinoma with prognostic and therapeutic avenues Mol. Oncol. (IF 6.6) Pub Date : 2024-04-23 Andrea Vallés‐Martí, Richard R. de Goeij‐de Haas, Alex A. Henneman, Sander R. Piersma, Thang V. Pham, Jaco C. Knol, Joanne Verheij, Frederike Dijk, Hans Halfwerk, Elisa Giovannetti, Connie R. Jiménez, Maarten F. Bijlsma
Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with a limited number of known driver mutations but considerable cancer cell heterogeneity. Phosphoproteomics provides a direct read‐out of aberrant signaling and the resultant clinically relevant phenotype. Mass spectrometry (MS)‐based proteomics and phosphoproteomics were applied to 42 PDAC tumors. Data encompassed over 19 936 phosphoserine
-
Academia and society should join forces to make anti‐cancer treatments more affordable Mol. Oncol. (IF 6.6) Pub Date : 2024-04-18 Anton Berns
Discovery research is the starting point for the development of more effective anti‐cancer treatments. It requires an interdisciplinary research environment with first‐class infrastructural support in which curiosity‐driven research can lead to new concepts for treating cancer. Translating such research findings to clinical practice requires complementary skills and infrastructures, including high‐quality
-
Identification of functional and diverse circulating cancer‐associated fibroblasts in metastatic castration‐naïve prostate cancer patients Mol. Oncol. (IF 6.6) Pub Date : 2024-04-18 Richell Booijink, Leon W. M. M. Terstappen, Eshwari Dathathri, Khrystany Isebia, Jaco Kraan, John Martens, Ruchi Bansal
In prostate cancer (PCa), cancer‐associated fibroblasts (CAFs) promote tumor progression, drug resistance, and metastasis. Although circulating tumor cells are studied as prognostic and diagnostic markers, little is known about other circulating cells and their association with PCa metastasis. Here, we explored the presence of circulating CAFs (cCAFs) in metastatic castration‐naïve prostate cancer
-
Proteome‐based molecular subtyping and therapeutic target prediction in gastric cancer Mol. Oncol. (IF 6.6) Pub Date : 2024-04-17 Changyuan Hu, Jiangning Song, Terry Kwok, Elizabeth V. Nguyen, Xian Shen, Roger J. Daly
-
Manzamine A reduces androgen receptor transcription and synthesis by blocking E2F8‐DNA interactions and effectively inhibits prostate tumor growth in mice Mol. Oncol. (IF 6.6) Pub Date : 2024-04-12 Dev Karan, Seema Dubey, Sumedha Gunewardena, Kenneth A. Iczkowski, Manohar Singh, Pengyuan Liu, Angelo Poletti, Yeun‐Mun Choo, Hui‐Zi Chen, Mark T. Hamann
-
MMP‐9‐dependent proteolysis of the histone H3 N‐terminal tail: a critical epigenetic step in driving oncogenic transcription and colon tumorigenesis Mol. Oncol. (IF 6.6) Pub Date : 2024-04-11 Yonghwan Shin, Sungmin Kim, Gangning Liang, Woojin An
Matrix metalloproteinase 9 (MMP‐9) is a member of the MMP family and has been recently identified as a nuclear protease capable of clipping histone H3 N‐terminal tails (H3NT). This MMP‐9‐dependent H3NT proteolysis is critical for establishing an active state of gene transcription during osteoclast differentiation and melanoma development. However, whether H3NT cleavage by MMP‐9 plays a similar role
-
TAS3681, an androgen receptor antagonist, prevents drug resistance driven by aberrant androgen receptor signaling in prostate cancer Mol. Oncol. (IF 6.6) Pub Date : 2024-04-10 Shohei Yoshida, Daisuke Kajiwara, Masanao Seki, Manabu Tayama, Yuki Tanaka, Hiroya Mizutani, Ryoto Fujita, Keisuke Yamamura, Shigeo Okajima, Masanori Asai, Kazuhisa Minamiguchi
-
A guide to ferroptosis in cancer Mol. Oncol. (IF 6.6) Pub Date : 2024-04-09 Fatma Isil Yapici, Christina M. Bebber, Silvia von Karstedt
-
-
DRD1 suppresses cell proliferation and reduces EGFR activation and PD‐L1 expression in NSCLC Mol. Oncol. (IF 6.6) Pub Date : 2024-04-04 Christopher E. Grant, Amy L. Flis, Leila Toulabi, Adriana Zingone, Emily Rossi, Krist Aploks, Heather Sheppard, Bríd M. Ryan
-
The Alcatraz-Strategy: a roadmap to break the connectivity barrier in malignant brain tumours Mol. Oncol. (IF 6.6) Pub Date : 2024-04-03 Matthias Schneider, Anna-Laura Potthoff, Georg Karpel-Massler, Patrick Schuss, Markus D. Siegelin, Klaus-Michael Debatin, Hugues Duffau, Hartmut Vatter, Ulrich Herrlinger, Mike-Andrew Westhoff
-
Subpar reporting of pre-analytical variables in RNA-focused blood plasma studies Mol. Oncol. (IF 6.6) Pub Date : 2024-04-02 Céleste Van Der Schueren, Philippe Decruyenaere, Francisco Avila Cobos, Johanna Bult, Jill Deleu, Laudonia Lidia Dipalo, Hetty Hilde Helsmoortel, Eva Hulstaert, Annelien Morlion, Elena Ramos Varas, Kathleen Schoofs, Wim Trypsteen, Eveline Vanden Eynde, Hanne Van Droogenbroeck, Kimberly Verniers, Jo Vandesompele, Anneleen Decock
-
Circulating cell‐free DNA methylation‐based multi‐omics analysis allows early diagnosis of pancreatic ductal adenocarcinoma Mol. Oncol. (IF 6.6) Pub Date : 2024-04-02 Guochao Zhao, Ruijingfang Jiang, Ying Shi, Suizhi Gao, Dansong Wang, Zhilong Li, Yuhong Zhou, Jianlong Sun, Wenchuan Wu, Jiaxi Peng, Tiantao Kuang, Yefei Rong, Jie Yuan, Shida Zhu, Gang Jin, Yuying Wang, Wenhui Lou
-
Oncolytic adenoviruses and immunopeptidomics: a convenient marriage Mol. Oncol. (IF 6.6) Pub Date : 2024-04-01 Marc Garcia-Moure, Andrew G. Gillard, Marta M. Alonso, Juan Fueyo, Candelaria Gomez-Manzano
-
TACE inhibition: a promising therapeutic intervention against AATF‐mediated steatohepatitis to hepatocarcinogenesis Mol. Oncol. (IF 6.6) Pub Date : 2024-04-01 Akshatha N. Srinivas, Diwakar Suresh, Prashant M. Vishwanath, Suchitha Satish, Prasanna K. Santhekadur, Saisudha Koka, Divya P. Kumar
-
The one‐carbon metabolic enzyme MTHFD2 promotes resection and homologous recombination after ionizing radiation Mol. Oncol. (IF 6.6) Pub Date : 2024-03-27 Petra Marttila, Nadilly Bonagas, Christina Chalkiadaki, Hannah Stigsdotter, Korbinian Schelzig, Jianyu Shen, Crystal M. Farhat, Amber Hondema, Julian Albers, Elisée Wiita, Azita Rasti, Ulrika Warpman Berglund, Ana Slipicevic, Oliver Mortusewicz, Thomas Helleday
-
Correction to: hnRNP-A1 binds to the IRES of MELOE-1 antigen to promote MELOE-1 translation in stressed melanoma cells Mol. Oncol. (IF 6.6) Pub Date : 2024-03-23
In the paper by Charpentier et al. [[1]], additional funding information should have been included within Acknowledgments, which is given below: This work was supported by the LabEx IGO program (n° ANR-11-LABX-0016) funded by the «Investment into the Future» French Government program, managed by the National Research Agency (ANR).
-
Pharmacological degradation of ATR induces antiproliferative DNA replication stress in leukemic cells Mol. Oncol. (IF 6.6) Pub Date : 2024-03-22 Anita G. Kansy, Ramy Ashry, Al-Hassan M. Mustafa, Abdallah M. Alfayomy, Markus P. Radsak, Yanira Zeyn, Matthias Bros, Wolfgang Sippl, Oliver H. Krämer
-
Tumour immunogenicity goes with the (mitochondrial electron) flow Mol. Oncol. (IF 6.6) Pub Date : 2024-03-22 Asma Ahmed, Stephen W. G. Tait
-
Minimally invasive biopsy-based diagnostics in support of precision cancer medicine Mol. Oncol. (IF 6.6) Pub Date : 2024-03-22 Bo Franzén, Gert Auer, Rolf Lewensohn
-
Postbiotics of Lacticaseibacillus paracaseiCECT 9610 and Lactiplantibacillus plantarumCECT 9608 attenuates store‐operated calcium entry and FAK phosphorylation in colorectal cancer cells Mol. Oncol. (IF 6.6) Pub Date : 2024-03-22 Alvaro Macias‐Diaz, Jose J. Lopez, Maria Bravo, Isaac Jardín, Waldo Luis Garcia‐Jimenez, Francisco J. Blanco‐Blanco, Rosario Cerrato, Juan A. Rosado
-
Immune checkpoint inhibitor monotherapy is sufficient to promote microenvironmental normalization via the type I interferon pathway in PD‐L1‐expressing head and neck cancer Mol. Oncol. (IF 6.6) Pub Date : 2024-03-21 Jeon Yeob Jang, Bok‐Soon Lee, Mei Huang, Chorong Seo, Ji‐Hye Choi, Yoo Seob Shin, Hyun Goo Woo, Chul‐Ho Kim
-
Combining VPS34 inhibitors with STING agonists enhances type I interferon signaling and anti‐tumor efficacy Mol. Oncol. (IF 6.6) Pub Date : 2024-03-20 Yasmin Yu, Madhumita Bogdan, Muhammad Zaeem Noman, Santiago Parpal, Elisabetta Bartolini, Kris Van Moer, Simone Caroline Kleinendorst, Kristine Bilgrav Saether, Lionel Trésaugues, Camilla Silvander, Johan Lindström, Jodi Simeon, Mary Jane Timson, Hikmat Al‐Hashimi, Bryan D. Smith, Daniel L. Flynn, Andrey Alexeyenko, Jenny Viklund, Martin Andersson, Jessica Martinsson, Katja Pokrovskaja Tamm, Angelo
-
Acetylated KHSRP impairs DNA‐damage‐response‐related mRNA decay and facilitates prostate cancer tumorigenesis Mol. Oncol. (IF 6.6) Pub Date : 2024-03-19 Haihua Yuan, Renjie Cai, Biying Chen, Qian Wang, Mengting Wang, Junyi An, Weishu An, Ye Tao, Jianxiu Yu, Bin Jiang, Yanjie Zhang, Ming Xu
-
Plasma membrane SK2 channel activity regulates migration and chemosensitivity of high‐grade serous ovarian cancer cells Mol. Oncol. (IF 6.6) Pub Date : 2024-03-14 Olivier Romito, Aude Lemettre, Aurélie Chantôme, Ophélie Champion, Noémie Couty, Lobna Ouldamer, Nadine Hempel, Mohamed Trebak, Caroline Goupille, Marie Potier‐Cartereau
-
Transcriptome‐wide gene expression outlier analysis pinpoints therapeutic vulnerabilities in colorectal cancer Mol. Oncol. (IF 6.6) Pub Date : 2024-03-12 Elisa Mariella, Gaia Grasso, Martina Miotto, Kristi Buzo, Nicole Megan Reilly, Pietro Andrei, Pietro Paolo Vitiello, Giovanni Crisafulli, Sabrina Arena, Giuseppe Rospo, Giorgio Corti, Annalisa Lorenzato, Carlotta Cancelliere, Ludovic Barault, Giulia Gionfriddo, Michael Linnebacher, Mariangela Russo, Federica Di Nicolantonio, Alberto Bardelli
-
From the creation of the European research area in 2000 to a Mission on cancer in Europe in 2021-lessons learned and implications Mol. Oncol. (IF 6.6) Pub Date : 2024-03-11 Julio Celis, Ulrik Ringborg
-
Unlocking the potential of tumor‐derived DNA in urine for cancer detection: methodological challenges and opportunities Mol. Oncol. (IF 6.6) Pub Date : 2024-03-11 Birgit M. M. Wever, Renske D. M. Steenbergen
-
RIP140 regulates transcription factor HES1 oscillatory expression and mitogenic activity in colon cancer cells Mol. Oncol. (IF 6.6) Pub Date : 2024-03-09 Nour Sfeir, Marilyn Kajdan, Stéphan Jalaguier, Sandrine Bonnet, Catherine Teyssier, Samuel Pyrdziak, Rong Yuan, Emilie Bousquet, Antonio Maraver, Florence Bernex, Nelly Pirot, Florence Boissière‐Michot, Audrey Castet‐Nicolas, Marion Lapierre, Vincent Cavaillès
-
The MYC–NFATC2 axis maintains the cell cycle and mitochondrial function in acute myeloid leukaemia cells Mol. Oncol. (IF 6.6) Pub Date : 2024-03-09 Shaun D. Patterson, Matthew E. Massett, Xu Huang, Heather G. Jørgensen, Alison M. Michie
-
-
Pleural mesothelioma (PMe): The evolving molecular knowledge of a rare and aggressive cancer Mol. Oncol. (IF 6.6) Pub Date : 2024-03-08 Manuel Rigon, Luciano Mutti, Michelangelo Campanella
-
Advanced strategies in improving the immunotherapeutic effect of CAR‐T cell therapy Mol. Oncol. (IF 6.6) Pub Date : 2024-03-08 Minmin Wang, Linzi Jia, Xiangpeng Dai, Xiaoling Zhang
-
Retraction: p53 loses grip on PIK3CA expression leading to enhanced cell survival during platinum resistance Mol. Oncol. (IF 6.6) Pub Date : 2024-03-04
The above article, published online on 29 April 2016 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the journal Editor-in-Chief, Kevin Ryan, FEBS Press, and John Wiley and Sons Ltd. The retraction has been agreed due to several image duplications in Figures 4B,E,G, and 5C,D, and inconsistencies between tumour luminescence images and the quantification in Figure
-
Dual role of GRHL3 in bladder carcinogenesis depending on histological subtypes Mol. Oncol. (IF 6.6) Pub Date : 2024-03-02 Franziska C. Lammert, Julia Pannhausen, Erik Noetzel, Florian Friedland, Julia Wirtz, Yannick Herfs, Sophie Leypold, Lin Gan, Ralf Weiskirchen, Tician Schnitzler, Ruth Knüchel, Jochen Maurer, Danny D. Jonigk, Michael Rose, Nadine T. Gaisa
-
The selenoenzyme type I iodothyronine deiodinase: a new tumor suppressor in ovarian cancer Mol. Oncol. (IF 6.6) Pub Date : 2024-03-02 Adi Alfandari, Dotan Moskovich, Avivit Weisz, Aviva Katzav, Debora Kidron, Mario Beiner, Dana Josephy, Aula Asali, Yael Hants, Yael Yagur, Omer Weitzner, Martin Ellis, Gilad Itchaki, Osnat Ashur‐Fabian
-
Clinical relevance and therapeutic predictive ability of hypoxia biomarkers in head and neck cancer tumour models Mol. Oncol. (IF 6.6) Pub Date : 2024-03-01 Tet Woo Lee, Dean C. Singleton, Julia K. Harms, Man Lu, Sarah P. McManaway, Amy Lai, Moana Tercel, Frederik B. Pruijn, Andrew M. J. Macann, Francis W. Hunter, William R. Wilson, Stephen M. F. Jamieson
-
Vitamin‐C‐dependent downregulation of the citrate metabolism pathway potentiates pancreatic ductal adenocarcinoma growth arrest Mol. Oncol. (IF 6.6) Pub Date : 2024-03-01 Aiora Cenigaonandia‐Campillo, Ana Garcia‐Bautista, Anxo Rio‐Vilariño, Arancha Cebrian, Laura del Puerto, José Antonio Pellicer, José Antonio Gabaldón, Horacio Pérez‐Sánchez, Miguel Carmena‐Bargueño, Carolina Meroño, Javier Traba, María Jesús Fernandez‐Aceñero, Natalia Baños‐Herraiz, Lorena Mozas‐Vivar, Estrella Núñez‐Delicado, Jesús Garcia‐Foncillas, Óscar Aguilera
-
The CK1ε/SIAH1 axis regulates AXIN1 stability in colorectal cancer cells Mol. Oncol. (IF 6.6) Pub Date : 2024-02-29 Mengfang Yan, Zijie Su, Xiaoyi Pang, Hanbin Wang, Han Dai, Jiong Ning, Shanshan Liu, Qi Sun, Jiaxing Song, Xibao Zhao, Desheng Lu
-
Cancer cachexia: biomarkers and the influence of age Mol. Oncol. (IF 6.6) Pub Date : 2024-02-28 Julia Geppert, Maria Rohm
-
PIKFYVE inhibitors trigger interleukin-24-dependent cell death of autophagy-dependent melanoma Mol. Oncol. (IF 6.6) Pub Date : 2024-02-27 Ajit Roy, Arup R. Chakraborty, Melvin L. DePamphilis
-
From monocyte‐derived macrophages to resident macrophages—how metabolism leads their way in cancer Mol. Oncol. (IF 6.6) Pub Date : 2024-02-27 Ummi Ammarah, Andreia Pereira‐Nunes, Marcello Delfini, Massimiliano Mazzone
-
STING activator 2′3′‐cGAMP enhanced HSV‐1‐based oncolytic viral therapy Mol. Oncol. (IF 6.6) Pub Date : 2024-02-24 Patricia Angela Sibal, Shigeru Matsumura, Toru Ichinose, Itzel Bustos‐Villalobos, Daishi Morimoto, Ibrahim R. Eissa, Mohamed Abdelmoneim, Mona Alhussein Mostafa Aboalela, Nobuaki Mukoyama, Maki Tanaka, Yoshinori Naoe, Hideki Kasuya
-
Regulation and tumor‐suppressive function of the miR‐379/miR‐656 (C14MC) cluster in cervical cancer Mol. Oncol. (IF 6.6) Pub Date : 2024-02-24 Sriharikrishnaa Srinath, Padacherri Vethil Jishnu, Vinay Koshy Varghese, Vaibhav Shukla, Divya Adiga, Sandeep Mallya, Sanjiban Chakrabarty, Krishna Sharan, Deeksha Pandey, Aniruddha Chatterjee, Shama Prasada Kabekkodu
-
MAP4K4 and WT1 mediate SOX6-induced cellular senescence by synergistically activating the ATF2–TGFβ2–Smad2/3 signaling pathway in cervical cancer Mol. Oncol. (IF 6.6) Pub Date : 2024-02-21 Han Zheng, Mingchen Liu, Shu Shi, Hongxin Huang, Xingwen Yang, Ziheng Luo, Yarong Song, Qiang Xu, Tingting Li, Lixiang Xue, Fengmin Lu, Jie Wang
-
The multispecies microbial cluster of Fusobacterium, Parvimonas, Bacteroides and Faecalibacterium as a precision biomarker for colorectal cancer diagnosis Mol. Oncol. (IF 6.6) Pub Date : 2024-02-17 Kelly Conde-Pérez, Pablo Aja-Macaya, Elena Buetas, Noelia Trigo-Tasende, Mohammed Nasser-Ali, Soraya Rumbo-Feal, Paula Nión, Elsa Martín-De Arribas, Lara S. Estévez, Begoña Otero-Alén, José F. Noguera, Ángel Concha, Simón Pardiñas-López, Miguel Carda-Diéguez, Igor Gómez-Randulfe, Nieves Martínez-Lago, Susana Ladra, Luis M. A. Aparicio, Germán Bou, Álex Mira, Juan A. Vallejo, Margarita Poza
-
Novel RAF-directed approaches to overcome current clinical limits and block the RAS/RAF node Mol. Oncol. (IF 6.6) Pub Date : 2024-02-16 Rossella Scardaci, Ewa Berlinska, Pietro Scaparone, Sandra Vietti Michelina, Edoardo Garbo, Silvia Novello, David Santamaria, Chiara Ambrogio
-
Immunosuppressive role of BDNF in therapy‐induced neuroendocrine prostate cancer Mol. Oncol. (IF 6.6) Pub Date : 2024-02-21 Yen‐Nien Liu, Wei‐Yu Chen, Ming‐Kun Liu, Hsiu‐Lien Yeh, Wei‐Hao Chen, Kuo‐Ching Jiang, Han‐Ru Li, Zi‐Qing Chen, Wan‐Hsin Wang, Wassim Abou‐Kheir, Yu‐Ching Wen
-
ITIH5 as a multifaceted player in pancreatic cancer suppression, impairing tyrosine kinase signaling, cell adhesion and migration Mol. Oncol. (IF 6.6) Pub Date : 2024-02-20 Jennifer Kosinski, Antonio Sechi, Johanna Hain, Sophia Villwock, Stefanie Anh Ha, Maximilian Hauschulz, Michael Rose, Florian Steib, Nadina Ortiz‐Brüchle, Lara Heij, Sanne L. Maas, Emiel P. C. van der Vorst, Thomas Knoesel, Annelore Altendorf‐Hofmann, Ronald Simon, Guido Sauter, Jan Bednarsch, Danny Jonigk, Edgar Dahl
-
An arms-race against resistance: leukemic stem cells and lineage plasticity Mol. Oncol. (IF 6.6) Pub Date : 2024-02-20 Alexander Waclawiczek, Aino-Maija Leppä, Simon Renders, Andreas Trumpp
-
TPX2 overexpression promotes sensitivity to dasatinib in breast cancer by activating YAP transcriptional signaling Mol. Oncol. (IF 6.6) Pub Date : 2024-02-15 Carlos Marugán, Natalia Sanz-Gómez, Beatriz Ortigosa, Ana Monfort-Vengut, Cristina Bertinetti, Ana Teijo, Marta González, Alicia Alonso de la Vega, María José Lallena, Gema Moreno-Bueno, Guillermo de Cárcer
-
PLK1 and FoxM1 expressions positively correlate in papillary thyroid carcinoma and their combined inhibition results in synergistic anti-tumor effects Mol. Oncol. (IF 6.6) Pub Date : 2024-02-15 Pratheesh Kumar Poyil, Abdul K. Siraj, Divya Padmaja, Sandeep Kumar Parvathareddy, Saravanan Thangavel, Khadija Alobaisi, Roxanne Diaz, Rafia Begum, Wael Haqawi, Saif S. Al-Sobhi, Fouad Al-Dayel, Khawla S. Al-Kuraya
-
IDH mutation, glioma immunogenicity, and therapeutic challenge of primary mismatch repair deficient IDH-mutant astrocytoma PMMRDIA: a systematic review Mol. Oncol. (IF 6.6) Pub Date : 2024-02-09 Olfat Ahmad, Tahani Ahmad, Stefan M. Pfister
-
Preclinical efficacy of carfilzomib in BRAF-mutant colorectal cancer models Mol. Oncol. (IF 6.6) Pub Date : 2024-02-13 Federica Maione, Daniele Oddo, Federica Galvagno, Chiara Falcomatà, Marta Pandini, Marco Macagno, Valeria Pessei, Ludovic Barault, Chiara Gigliotti, Alessia Mira, Giorgio Corti, Simona Lamba, Chiara Riganti, Barbara Castella, Massimo Massaia, Roland Rad, Dieter Saur, Alberto Bardelli, Federica Di Nicolantonio
Serine/threonine-protein kinase B-raf (BRAF) mutations are found in 8–15% of colorectal cancer patients and identify a subset of tumors with poor outcome in the metastatic setting. We have previously reported that BRAF-mutant human cells display a high rate of protein production, causing proteotoxic stress, and are selectively sensitive to the proteasome inhibitors bortezomib and carfilzomib. In this
-
Recurrence/prognosis estimation using a molecularly positive surgical margin-based model calls for alternative curative strategies in pIIIA/N2 NSCLC Mol. Oncol. (IF 6.6) Pub Date : 2024-02-07 Li Li, Kewen He, Tao Zhou, Yang Xu, Jiaohui Pang, Qingxi Yu, Yongsheng Gao, Hongjin Shi, He Zhu, Mengke Li, Jinming Yu, Shuanghu Yuan
-
High FLT3 expression increases immune-cell infiltration in the tumor microenvironment and correlates with prolonged disease-free survival in patients with non-small cell lung cancer Mol. Oncol. (IF 6.6) Pub Date : 2024-02-07 Łukasz Kuncman, Magdalena Orzechowska, Tomasz Milecki, Jakub Kucharz, Jacek Fijuth
-
Global pannexin 1 deletion increases tumor-infiltrating lymphocytes in the BRAF/Pten mouse melanoma model Mol. Oncol. (IF 6.6) Pub Date : 2024-02-07 Rafael E. Sanchez-Pupo, Garth A. Finch, Danielle E. Johnston, Heather Craig, Rober Abdo, Kevin Barr, Steven Kerfoot, Lina Dagnino, Silvia Penuela
-
-
Links between melanoma germline risk loci, driver genes and comorbidities: insight from a tissue-specific multi-omic analysis Mol. Oncol. (IF 6.6) Pub Date : 2024-02-03 Michael Pudjihartono, Evgeniia Golovina, Tayaza Fadason, Justin M. O'Sullivan, William Schierding
-
Genetic and non-genetic drug resistance: Darwin or Lamarck? Mol. Oncol. (IF 6.6) Pub Date : 2024-02-02 Mariangela Russo